Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.0156 | 0.1256 | 0.5 |
Echinococcus multilocularis | serotonin receptor | 0.0262 | 0.2718 | 0.2718 |
Loa Loa (eye worm) | hypothetical protein | 0.0156 | 0.1256 | 0.2943 |
Echinococcus multilocularis | poly (ADP ribose) polymerase 1 | 0.0285 | 0.3025 | 0.3025 |
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.0156 | 0.1256 | 0.5 |
Brugia malayi | WGR domain containing protein | 0.0285 | 0.3025 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0217 | 0.2088 | 0.6958 |
Entamoeba histolytica | poly(ADP-ribose) polymerase, putative | 0.0285 | 0.3025 | 0.5 |
Echinococcus multilocularis | serotonin receptor | 0.0262 | 0.2718 | 0.2718 |
Echinococcus multilocularis | biogenic amine (5HT) receptor | 0.079 | 1 | 1 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.0285 | 0.3025 | 0.228 |
Echinococcus granulosus | biogenic amine 5HT receptor | 0.0262 | 0.2718 | 0.2478 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.0156 | 0.1256 | 0.0322 |
Schistosoma mansoni | biogenic amine (5HT) receptor | 0.079 | 1 | 1 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0296 | 0.3179 | 0.5 |
Echinococcus multilocularis | poly (adp ribose) polymerase 2 | 0.0156 | 0.1256 | 0.1256 |
Echinococcus granulosus | poly ADP ribose polymerase 1 | 0.0285 | 0.3025 | 0.2796 |
Echinococcus granulosus | poly adp ribose polymerase 2 | 0.0156 | 0.1256 | 0.0968 |
Loa Loa (eye worm) | hypothetical protein | 0.0262 | 0.2718 | 1 |
Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0262 | 0.2718 | 0.194 |
Trypanosoma brucei | poly(adp-ribose) polymerase | 0.0156 | 0.1256 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0262 | 0.2718 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.